The Plain Record

Neutral daily news — clear headlines, complete facts.

On the Hill

FDA Nominee Heidi Overton Faces Uncertainty Ahead of Senate Committee Vote

Dr. Heidi Overton faces a committee vote Wednesday amid reports that several Republican senators may not support her nomination to lead the FDA.

Background: Impeachment and removal

Published November 17, 2026 at 6:51 PM EST

The short answer

Dr. Heidi Overton faces a committee vote Wednesday amid reports that several Republican senators may not support her nomination to lead the FDA. President Donald Trump’s nominee to lead the Food and Drug Administration (FDA), Dr. Heidi Overton, is facing difficulty securing enough support for confirmation from the Senate Health, Education, Labor and Pensions (HELP) Committee.

FDA Nominee Heidi Overton Faces Uncertainty Ahead of Senate Committee Vote

The Facts

Who
Dr. Heidi Overton, President Trump, and members of the Senate HELP Committee.
What
The confirmation status of Dr. Heidi Overton as FDA Commissioner.
When
Ahead of a scheduled Wednesday morning committee vote.
Where
Washington, D.C.
Why
Overton lacks confirmed support from several Republican senators on the committee, potentially leading the White House to seek an acting commissioner instead.

President Donald Trump’s nominee to lead the Food and Drug Administration (FDA), Dr. Heidi Overton, is facing difficulty securing enough support for confirmation from the Senate Health, Education, Labor and Pensions (HELP) Committee. Sources reported that the committee, which is scheduled to vote on the nomination Wednesday, lacks enough Republican votes to advance her. None of the committee's Democratic members are expected to support her nomination.

The difficulty stems from Overton’s previous work on the Domestic Policy Council, her testimony regarding the abortion drug mifepristone, and her execution of pro-vaping policies. Sen. Josh Hawley (R-MO) expressed skepticism after Overton declined to detail how she would handle a safety study of the drug. Additionally, Sens. Susan Collins (R-ME) and Lisa Murkowski (R-AK) have not declared their voting intentions, with Murkowski questioning if Overton would restrict access to the medication. The anti-abortion group Susan B. Anthony has requested a delay in the confirmation process, while Calley Means, a former advisor to the Health and Human Services Secretary, has also urged followers to block her.

The White House has begun identifying alternative candidates, including those who could serve in an acting capacity. Such a move would allow the administration to bypass the Senate confirmation process during the current three-week legislative window. Sources also indicated that Sen. Roger Marshall (R-KS), who recently lost his reelection bid, is seeking the post. Overton’s supporters cite her medical background and endorsements from two former FDA commissioners as evidence of her professional qualifications.

For specific groups, the outcome of this confirmation will impact access to certain medical treatments and consumer products. This includes the more than 50% of people in the U.S. who utilize mifepristone for abortions, as the agency determines how the drug is dispensed, including through mail orders. Additionally, the nomination involves the future of the vaping industry; President Trump has pledged to protect vaping as a smoking alternative, despite concerns from former chief Marty Makary regarding flavored products that may appeal to children.

The next steps for the FDA leadership will be determined by the HELP Committee's vote scheduled for Wednesday morning. If Overton’s nomination is pulled or fails to advance, the administration must decide whether to put forward a new nominee or install an acting commissioner. This decision comes during the final weeks of Republican control of the current Congress. Following the committee vote, any successful nomination would then require a full vote on the Senate floor.

Timeline of what happened

Key dates and decisions, in the order they occurred.

  1. November 8, 2024

    Dr. Marty Makary issues statement on resignation

    The former chief alleged pressure from officials to approve flavored vapes.

  2. November 18, 2026

    Scheduled Senate HELP Committee vote

    The committee is set to vote on whether to advance Overton's nomination to the floor.

Summaries are written by The Plain Record to state the facts of a story plainly and without political slant. Drafted with AI assistance and checked against the source record before publication. See how we report, or report a correction.

← Back to the front page

Questions readers ask

What happened: FDA Nominee Heidi Overton Faces Uncertainty Ahead of Senate Committee Vote?

President Donald Trump’s nominee to lead the Food and Drug Administration (FDA), Dr. Heidi Overton, is facing difficulty securing enough support for confirmation from the Senate Health, Education, Labor and Pensions (HELP) Committee. Sources reported that the committee, which is scheduled to vote on the nomination Wednesday, lacks enough Republican votes to advance her.

Who is involved?

Dr. Heidi Overton, President Trump, and members of the Senate HELP Committee.

When did this happen?

Ahead of a scheduled Wednesday morning committee vote.

Where did this happen?

Washington, D.C.

Why does this matter?

Overton lacks confirmed support from several Republican senators on the committee, potentially leading the White House to seek an acting commissioner instead.